CARsgen (科济药业)

CARsgen Therapeutics Holdings Limited (科济药业) is a biopharmaceutical company with operations in China and the United States, focused on developing innovative CAR T-cell therapies for hematologic malignancies and solid tumors. Founded in 2014 by Dr. Zonghai Li, CARsgen was one of the first enterprises to enter the CAR-T therapeutic industry in China and listed on the Hong Kong Stock Exchange (HKEX) in June 2021. The company's proprietary THANK-uCAR® technology platform and lead asset Zevor-cel (SaikaiZe) — approved in China for multiple myeloma — exemplify its commitment to making next-generation cell therapies more accessible and effective.